2021
TIL in Melanoma—Similar Approaches, Different Results, Unanswered Questions
Sznol M. TIL in Melanoma—Similar Approaches, Different Results, Unanswered Questions. Clinical Cancer Research 2021, 27: 5156-5157. PMID: 34413160, DOI: 10.1158/1078-0432.ccr-21-2450.Peer-Reviewed Original ResearchMeSH KeywordsHumansImmunotherapy, AdoptiveLymphocytes, Tumor-InfiltratingMelanomaMolecular Targeted TherapyNeoplasms, Second Primary
2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design
Khushalani NI, Diab A, Ascierto PA, Larkin J, Sandhu S, Sznol M, Koon HB, Jarkowski A, Zhou M, Statkevich P, Geese WJ, Long GV. Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future Oncology 2020, 16: 2165-2175. PMID: 32723187, DOI: 10.2217/fon-2020-0351.Peer-Reviewed Original ResearchConceptsMetastatic melanomaKey secondary end pointEnd pointSafety/tolerabilityObjective response ratePD-1 inhibitorsPrimary end pointSecondary end pointsFirst-line therapyProgression-free survivalNatural killer cellsOverall survivalSurvival benefitAdvanced melanomaKiller cellsClinical trialsEffector TClinical activityNivolumabBempegaldesleukinResponse rateMelanomaPathway agonistStudy designPhase IIIReversing Resistance to Checkpoint Inhibitors and Targeted Therapy in Metastatic Melanoma.
Sznol M. Reversing Resistance to Checkpoint Inhibitors and Targeted Therapy in Metastatic Melanoma. Clinical Advances In Hematology And Oncology 2020, 18: 408-410. PMID: 32903252.Peer-Reviewed Original Research
2018
Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis
Kaufman HL, Schwartz LH, William WN, Sznol M, Fahrbach K, Xu Y, Masson E, Vergara-Silva A. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. Journal Of Cancer Research And Clinical Oncology 2018, 144: 2245-2261. PMID: 30132118, DOI: 10.1007/s00432-018-2738-x.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsEndpoint DeterminationHumansMolecular Targeted TherapyNeoplasmsRandomized Controlled Trials as TopicSurvival AnalysisConceptsImmune checkpoint blockersOS hazard ratioPFS hazard ratioHazard ratioOverall survivalPFS ratesOS ratesCheckpoint blockersPooled analysisClinical endpointsSolid tumor patientsChemotherapy armTreatment armsOdds ratioTumor patientsPredictive valueChemotherapySystematic reviewImperfect surrogatePatientsEndpointBlockersCongress proceedingsSurvivalArm
2017
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer
Zloza A, Karolina Palucka A, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA, Wong KK, Bosenberg MW. Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer. Journal For ImmunoTherapy Of Cancer 2017, 5: 77. PMID: 28923102, PMCID: PMC5604351, DOI: 10.1186/s40425-017-0278-6.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsDisease Models, AnimalHumansImmunotherapyMiceMolecular Targeted TherapyNeoplasmsSocieties, ScientificTumor MicroenvironmentConceptsImmunotherapy of cancerCancer immunologyHumanized modelImmunotherapy researchImmune-targeted therapiesAntitumor immune responseCancer immunotherapy researchCancer immunotherapyImmune responseMurine modelMouse modelImmunotherapyPredictive valueSubsequent panel discussionNational HarborAnnual MeetingImmunologyDrug developmentCancerMiceFuture directionsImmunocompetentTherapyCancer modelingPhase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, Di Gravio D, Huang B, Gambhire D, Chen Y, Thall AD, Pathan N, Schmidt EV, Chow LQM. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clinical Cancer Research 2017, 23: 5349-5357. PMID: 28634283, DOI: 10.1158/1078-0432.ccr-17-1243.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyDiagnostic ImagingDrug MonitoringFemaleHumansImmunoglobulin GMaleMaximum Tolerated DoseMiddle AgedMolecular Targeted TherapyNeoplasm StagingNeoplasmsRetreatmentT-Lymphocyte SubsetsTreatment OutcomeTumor Necrosis Factor Receptor Superfamily, Member 9ConceptsAdvanced solid tumorsSolid tumorsTreatment-emergent adverse eventsPeripheral blood CD8Phase Ib studyTreatment-related discontinuationsDose-limiting toxicityCostimulatory receptor 4Event continual reassessment methodT cell costimulatory receptor 4Clin Cancer ResSupport further investigationBlood CD8Partial responseAdverse eventsDose escalationReceptor 4Clinical activityT cellsIb studyCombination treatmentContinual reassessment methodPatientsGrade 1Cancer Res
2011
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.
Flies DB, Sandler BJ, Sznol M, Chen L. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. The Yale Journal Of Biology And Medicine 2011, 84: 409-21. PMID: 22180678, PMCID: PMC3238327.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsB7-H1 AntigenHumansImmunotherapyMolecular Targeted TherapyNeoplasmsProgrammed Cell Death 1 ReceptorSignal TransductionConceptsB7-H1/PDTumor-associated antigensImmune responseCancer immunotherapyMolecular pathwaysCancer-specific immune responsesImmune-mediated destructionSpecific immune responseCancer immunotherapy researchAnti-cancer effectsCoinhibitory functionImmunotherapeutic modalitiesCoinhibitory moleculesClinical evidenceImmunotherapy researchMalignant diseaseNew immunotherapeuticsImmune cellsImmune functionStromal cellsCancerMonoclonal antibodiesCancer cellsImmunotherapyCurrent knowledgeMolecular Markers of Response to Treatment for Melanoma
Sznol M. Molecular Markers of Response to Treatment for Melanoma. The Cancer Journal 2011, 17: 127-133. PMID: 21427556, DOI: 10.1097/ppo.0b013e318212dd5a.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntineoplastic AgentsBiomarkers, TumorHumansImmunotherapyMelanomaMolecular Targeted TherapyConceptsImmune therapyAnti-tumor immune responseInitial high response rateStandard of careFraction of patientsUseful predictive biomarkerHigh response rateMost patientsMetastatic melanomaPredictive biomarkersClinical activityImmune responseIndividual patientsPotent small molecule inhibitorsDurable benefitMultiple active agentsSmall molecule inhibitorsResponse ratePatientsMutant BRAFOverall populationTherapyMolecule inhibitorsMelanomaTumors